Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Prostate cancer
State:  North Carolina
Country:  U.S.A.
Results 1-25 of 37 for your search:
Start Over
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients with Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 0924, NCI-2011-02674, CDR0000701128, PRTOG-0924_A03PAMDREVW01, NCT01368588
Androgen Deprivation Therapy and Orteronel or Bicalutamide in Treating Patients with Newly Diagnosed Metastatic Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: S1216, NCI-2012-02876, SWOG-S1216, NCT01809691
Enzalutamide with or without Abiraterone Acetate and Prednisone in Treating Patients with Castration-Resistant Metastatic Prostate Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A031201, NCI-2013-01737, CALGB-A031201, NCT01949337
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: MDV3100-14, NCI-2013-02393, NCT02003924
Surgery or Non-surgical Management in Treating Patients with Intra-abdominal Cancer and Bowel Obstruction
Status: Active
Phase: Phase III
Type: Supportive care
Age: 18 and over
Trial IDs: S1316, NCI-2014-01497, SWOG/S1316, NCT02270450
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: MDV3100-13, NCI-2015-00824, NCT02319837
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ARMOR3-SV, NCI-2015-00996, NCT02438007
A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: INO-VT-464-CL-001, NCI-2014-00229, VMT-VT-464-CL-001, NCT02012920
A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: INO-VT-464-CL-004, NCI-2015-00285, NCT02361086
Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: INCB 54828-101, NCI-2015-00611, NCT02393248
Abiraterone Acetate, Radiation Therapy, and Hormone Therapy in Treating Patients with Unfavorable-Risk Localized Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 20 to 80
Trial IDs: Pro00044071, NCI-2013-01803, NCT01717053
Abiraterone Acetate Alone, or Abiraterone Acetate and Degarelix, or Degarelix Alone in Treating Patients with Prostate Cancer Previously Treated with Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-187, NCI-2012-03130, c11-092, NCT01751451
Carbohydrate-Restricted Diet in Treating Patients with Previously Treated Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 20 and over
Trial IDs: Pro00041857, NCI-2013-00581, 00041857, Amd020_Pro00041857, NCT01763944
CYT107 after Vaccine Treatment (Provenge) in Patients with Metastatic Hormone-Resistant Prostate Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CITN12-03, NCI-2013-00998, CITN12-03 IL7, NCT01881867
Abiraterone Acetate and Prednisone in Treating African American and Caucasian Patients with Hormone-Resistant Metastatic Prostate Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Pro00046383, NCI-2014-00260, 212082PCR2018, DUMC Pro00046383, NCT01940276
Androgen Deprivation Therapy, Enzalutamide, and Radiation Therapy in Treating Patients with Recurrent Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: Pro00049865, NCI-2014-01161, DUMC Pro00049865, NCT02057939
Abiraterone Acetate with or without Cabazitaxel in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-046, NCI-2014-01894, c12-108, NCT02218606
Exercise Training in Improving Quality of Life in Patients with Hormone Naïve Prostate Cancer Receiving Enzalutamide and Androgen Deprivation Therapy
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Pro00053924, NCI-2014-02541, NCT02256111
Radium Ra 223 Dichloride in Reducing Pain in Patients with Symptomatic Metastatic Hormone-Resistant Prostate Cancer
Status: Active
Phase: Phase II
Type: Supportive care
Age: 18 and over
Trial IDs: 14-098, NCI-2014-02542, c13-124, NCT02278055
Once-daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: INO-VT-464-CL-003, NCI-2015-01076, VMT-VT-464-CL-003, NCT02445976
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EMR 100070-001, NCI-2013-02214, 2013-002834-19, NCT01772004
Stereotactic Body Radiation Therapy in Treating Patients with Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer
Status: Active
Phase: Phase I
Type: Natural history/Epidemiology, Treatment
Age: 18 and over
Trial IDs: NRG-BR001, NCI-2014-00702, NCT02206334
Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 to 90
Trial IDs: PCa-001, NCI-2015-01363, NCT02514213
Low-Carbohydrate Diet in Preventing Insulin Resistance and Weight Gain in Patients with Prostate Cancer Planning to Undergo Hormone Therapy
Status: Active
Phase: No phase specified
Type: Supportive care
Age: 18 and over
Trial IDs: Pro00010519, NCI-2013-01874, NCT00932672
Immune Activation in Patients with Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T Immunotherapy
Status: Active
Phase: No phase specified
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: Pro00047231, NCI-2015-02074, NCT02036918
Start Over